Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turkey’s Pharmaceutical Budget Nearing Decision; Pharma Waits For Impact

This article was originally published in PharmAsia News

Executive Summary

Pharma companies have weathered three rounds of price cuts in recent years, but there are signs that the worst may be over for now in Turkey.

You may also be interested in...



AiFD Vice Chairman Engin Guner On Price Cuts In Turkey And Mounting Pressure On Industry: An Interview With PharmAsia News (Part 1 of 2)

A former law maker and leader of the Turkish parliamentary delegation to the Council of Europe, Engin Guner knows about how policy works. The vice chairman of the Association of Research-Based Pharmaceutical Companies (AiFD), which represents Big Pharma in Turkey, emphasizes that government price cuts and related policy challenges, combined with currency depreciation, are taking a heavy toll on the industry.

Turkey: International Medtechs Demand Stable Pricing And On-Time Payments

Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.


Turkey’s Domestic Vaccine Production Drive Prompts New Partnerships

The Turkish government’s drive to establish domestic manufacturing for vaccines is showing tentative signs of getting off the ground. New partnerships are forming between Turkish and international partners. However, lack of local know-how is hampering progress.

 

Topics

Related Companies

UsernamePublicRestriction

Register

SC081943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel